10-1074 vs BNT351

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV envelope · full HIV pipeline

10-1074

Developed by Gilead Sciences under a licence from The Rockefeller University

Phase 2 in HIVmonoclonal antibody
Weak signal

NCT03707977 · Phase 1/2 · completed

This was a small, nonrandomized, open-label study without a comparator arm, enrolling 30 children overall and evaluating viral-load and safety outcomes descriptively. All participants received 10-1074 together with a second antibody, VRC01LS, so the results describe the dual-antibody regimen, not 10-1074 alone. The primary viral outcomes were reported as 11 of 25 below 400 copies/mL and 10 of 25 below 40 copies/mL at Week 24, but there was no controlled comparison or formal significance test.

Reported efficacy

Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant); Severity of Treatment-associated AEs (Number of Participants With Grade 3 or Higher Related AEs) (Measured until 30 days after study completion for each participant); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 400 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 40 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2): Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant): Group PK-A: ART + VRC01LS 4 Participants | Group PK-B: ART + 10-1074 1 Participants | Steps 1-3 Participants (ART + 10-1074 + VRC01LS) 19 Participants (not_applicable)

Result source: NCT03707977

BNT351

Developed by BioNTech

Phase 1 in HIVmonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT07392372 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpoint10-1074BNT351
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

10-1074
—Not reported
BNT351
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

10-1074
—Not reported
BNT351
—Not reported

CD4 count, change (week 48)

10-1074
—Not reported
BNT351
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BNT351: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. 10-1074: 3 of 4 rows · BNT351: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metric10-1074
Dropout rate
0%Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
—PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
Discontinued due to AEs
—Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
—PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
—Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
Serious AEs
—Group PK-B: ART + 10-1074
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 3 more results
0%PK Step (ART + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
0%Step 1 (ART + VRC01LS + 10-1074)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
4%Step 2 (VRC01LS + 10-1074 Only)
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
Most frequent reported AEs
rhinorrhoea 83.3%
cough 50%
pyrexia 50%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
show 2 more results
neutrophil count decreased 35.7%
haemoglobin decreased 28.6%
cough 25%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2
cough 44%
upper respiratory tract infection 32%
haemoglobin decreased 28%
NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 10-1074's landscape · BNT351's landscape